HSD17B13 and hepatocellular carcinoma: In patients with alcoholic liver disease, the proportion of a loss of function variant (rs72613567) in 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) carriers with HCC was significantly lower (32%) than in chronic liver disease patients without HCC (40%) [102].